Multiple Endocrine Neoplasia Type 2a
What's New
Last Posted: May 06, 2024
- [Multiple endocrine neoplasia and very early onset inflammatory bowel disease. An unexpected association].
Santiago I Rossi, et al. Medicina 2024 0 (2) 347-350 - Germline founder variant c.1998delinsTTCT in the RET oncogene: a cohort study in 15 Belgian families.
Axelle Vuylsteke, et al. European journal of endocrinology 2023 0 (3) 402-408 - Is new American Thyroid Association risk classification for hereditary medullary thyroid carcinoma applicable to Chinese patients? A single-center study.
Zhang Xiwei, et al. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2017 0 (3) 223-230 - The Clinical Spectrum of Multiple Endocrine Neoplasia Type 2A with Cutaneous Lichen Amyloidosis in Ethnic Han Chinese.
Qi Xiao-Ping, et al. Cancer investigation 2018 0 (2) 141-151 - Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
Elisei Rossella, et al. Annales d'endocrinologie 2019 0 (3) 187-190 - Variability in Medullary Thyroid Carcinoma in RET L790F Carriers: A Case Comparison Study of Index Patients.
Mathiesen Jes Sloth, et al. Frontiers in endocrinology 2020 0 251 - Medullary thyroid cancer with RET V804M mutation: more indolent than expected?
Frisco Nicholas A, et al. Surgery 2022 0 (1) 260-267 - Pheochromocytoma recurrence in hereditary disease: does a cortical-sparing technique increase recurrence rate?
Shirali Aditya S, et al. Surgery 2022 0 (1) 26-34 - Case Report: A Case of Moyamoya Syndrome Associated With Multiple Endocrine Neoplasia Type 2A.
Matano Fumihiro, et al. Frontiers in endocrinology 2021 0 703410 - Different RET gene mutation-induced multiple endocrine neoplasia type 2A in 3 Chinese families.
Liu Qiuli, et al. Medicine 2017 0 (3) e5967 - Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A.
Lesueur Fabienne, et al. Cancer research 2006 0 (2) 1177-80 - Topographic molecular profile of pheochromocytomas: role of somatic down-regulation of mismatch repair.
Blanes Alfredo, et al. The Journal of clinical endocrinology and metabolism 2006 0 (3) 1150-8 - CLINGEN Actionability Report for Multiple Endocrine Neoplasia IIA, Familial Medullary Thyroid Cancer - RET
ClinGen Actionability Working Group - The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.
Grey William, et al. Endocrine pathology 2016 10 - A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
Opsahl Else Marie, et al. Thyroid : official journal of the American Thyroid Association 2016 7 - Clinical significance of RET mutation screening in a pedigree of multiple endocrine neoplasia type 2A.
Ying Rongbiao, et al. Molecular medicine reports 2016 6 - Presence of the RET Cys634Tyr mutation and Gly691Ser functional polymorphism in Iranian families with multiple endocrine neoplasia type 2A.
Aghdam Maryam Nasiri, et al. Hormones (Athens, Greece) 2016 1 - Therapeutic Effectiveness of Screening for Multiple Endocrine Neoplasia Type 2A.
Machens Andreas et al. The Journal of clinical endocrinology and metabolism 2015 Jul 100(7) 2539-45 - Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
Wang Junyi, et al. Familial cancer 2015 8 - Exome sequencing reveals mutant genes with low penetrance involved in MEN2A-associated tumorigenesis.
Cai Jie, et al. Endocrine-related cancer 2015 2 (1) 23-33
More
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: